BR0009914A - Medication, and, uses of an inhibitor, and a human volume-regulated human h-sgk kinase activator - Google Patents

Medication, and, uses of an inhibitor, and a human volume-regulated human h-sgk kinase activator

Info

Publication number
BR0009914A
BR0009914A BR0009914-7A BR0009914A BR0009914A BR 0009914 A BR0009914 A BR 0009914A BR 0009914 A BR0009914 A BR 0009914A BR 0009914 A BR0009914 A BR 0009914A
Authority
BR
Brazil
Prior art keywords
human
inhibitor
regulated
medication
sgk
Prior art date
Application number
BR0009914-7A
Other languages
Portuguese (pt)
Inventor
Florian Lang
Siegfried Waldegger
Carsten Wagner
Stefan Broeer
Karin Klingel
Original Assignee
Florian Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florian Lang filed Critical Florian Lang
Publication of BR0009914A publication Critical patent/BR0009914A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MEDICAMENTO, E, USOS DE UM INIBIDOR, E DE UM ATIVADOR DE QUINASE H-SGK HUMANA REGULADA POR VOLUME CELULAR". A invenção refere-se a medicamentos que contém inibidores ou ativadores de quinase h-sgk humana regulada por volume celular. Medicamentos deste tipo são apropriados para o tratamento de condições, em que uma expressão aumentada ou reduzida de h-sgk é identificada."MEDICINE, AND, USES OF AN INHIBITOR, AND OF A HUMAN H-SGK KINASE ACTIVATOR REGULATED BY CELL VOLUME". The invention relates to medicaments that contain cell volume-regulated human h-sgk kinase inhibitors or activators. Medicines of this type are appropriate for the treatment of conditions, in which an increased or reduced expression of h-sgk is identified.

BR0009914-7A 1999-04-20 2000-04-19 Medication, and, uses of an inhibitor, and a human volume-regulated human h-sgk kinase activator BR0009914A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19917990A DE19917990A1 (en) 1999-04-20 1999-04-20 Medicament containing inhibitors of cell volume regulated human kinase h-sgk
PCT/EP2000/003578 WO2000062781A1 (en) 1999-04-20 2000-04-19 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk

Publications (1)

Publication Number Publication Date
BR0009914A true BR0009914A (en) 2002-01-08

Family

ID=7905297

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009914-7A BR0009914A (en) 1999-04-20 2000-04-19 Medication, and, uses of an inhibitor, and a human volume-regulated human h-sgk kinase activator

Country Status (18)

Country Link
EP (1) EP1171131A1 (en)
JP (1) JP2002542196A (en)
KR (1) KR100718900B1 (en)
CN (1) CN1351496A (en)
AU (1) AU779941B2 (en)
BR (1) BR0009914A (en)
CA (1) CA2369078A1 (en)
CZ (1) CZ20013778A3 (en)
DE (1) DE19917990A1 (en)
HU (1) HUP0200819A3 (en)
MX (1) MXPA01010588A (en)
NO (1) NO20015054L (en)
PL (1) PL198427B1 (en)
RU (1) RU2288718C9 (en)
SK (1) SK14972001A3 (en)
UA (1) UA79066C2 (en)
WO (1) WO2000062781A1 (en)
ZA (1) ZA200108610B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042137A1 (en) * 2000-08-28 2002-03-14 Florian Lang sgk2 and sgk3 as diagnostic and therapeutic targets
DE10113876A1 (en) * 2001-03-21 2002-09-26 Eberhard Karls Uni Medizinisch Quantitative diagnosis of genetically related hypertension, by correlating blood pressure with overexpression or modification of human sgk family proteins
ES2329117T3 (en) 2001-04-27 2009-11-23 Cold Spring Harbor Laboratory RELIEF OF MEMORY DEFICITS AND THE COMPONENTS OF THE PSYCHIATRIC DYSFUNCTION MEMORY ALTERING THE ACTIVITY OF THE ATIPIC PKM.
DE10149393A1 (en) * 2001-09-28 2003-04-24 Florian Lang Detecting the expression of serum and glucocorticoid-dependent kinase-1 (sgk1), for diagnosing coagulative diseases, diabetes, tumors, diabetes and autoimmune diseases, comprises using an antibody against sgk1
DE10225844A1 (en) * 2002-06-04 2003-12-18 Lang Florian sgk and nedd as diagnostic and therapeutic targets
DE10305212A1 (en) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Use of the sgk gene family for the diagnosis and therapy of cataracts and glaucoma
CA2517958A1 (en) * 2003-03-03 2004-09-16 Florian Lang Sgk1 as diagnostic and therapeutic target
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
DE10346913A1 (en) * 2003-10-09 2005-05-04 Merck Patent Gmbh acylhydrazone
WO2005084702A1 (en) * 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. Agent for preventing and treating organ fibrosis
JP2007527875A (en) * 2004-03-11 2007-10-04 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Methods for inhibiting fibrosis
CN1929846A (en) * 2004-03-11 2007-03-14 默克专利有限公司 Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
WO2005106491A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1)
WO2005118832A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase-like protein (sgkl)
DE102004030987A1 (en) * 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituted (3-hydroxyphenyl) -acetic acid benzylidene hydrazides
MX2007001155A (en) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Methods, systems, and computer program products for providing presence gateway functionality in a telecommunications network.
DE102005001053A1 (en) * 2005-01-07 2006-07-20 Merck Patent Gmbh Square acid derivatives
DE102005015255A1 (en) * 2005-04-04 2006-10-05 Merck Patent Gmbh New acylhydrazide compounds are signal transduction kinase inhibitor, useful for treating and/or preventing diseases, e.g. diabetes, adiposity, metabolic syndrome, cancer and tumor cells
DE102005035742A1 (en) * 2005-07-29 2007-02-01 Merck Patent Gmbh New cyclobut-3-ene-1,2-dione derivatives are kinase inhibitors useful for treating e.g. cancer, hypertension, diabetes, glaucoma and bacterial infections
DE102005039541A1 (en) * 2005-08-22 2007-03-22 Merck Patent Gmbh 3-oxo-indazol-square acid derivatives
DE102007002717A1 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclic indazole derivatives
DE102007022565A1 (en) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclic indazole derivatives
EP2014651A1 (en) * 2007-07-12 2009-01-14 Exonhit Therapeutics SA Compounds and methods for modulating Rho GTPases
DE102008010362A1 (en) 2008-02-18 2009-08-20 Florian Prof. Dr. Lang Sgk1 as a therapeutic and diagnostic target for viral diseases
DE102008010363A1 (en) 2008-02-18 2009-08-20 Lang, Florian, Prof. Dr.med. Sgk1 as a therapeutic and diagnostic target for carcinomatous diseases
DE102008010361A1 (en) 2008-02-18 2009-08-20 Merck Patent Gmbh sgk1 inhibitors for the prophylaxis and / or therapy of viral diseases and / or carcinomas
DE102008029072A1 (en) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis
DE102008038220A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh oxadiazole
DE102008038221A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-azaindole derivatives
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
DE102008059133A1 (en) 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorophenyl diacylhydrazide derivatives
EP2637650A2 (en) 2010-11-10 2013-09-18 National Jewish Health Methods to test allergic conditions
CN107875153A (en) * 2017-11-16 2018-04-06 上海壹志医药科技有限公司 The medicinal usage of Des-N-methylchelerythrine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
US5242397A (en) * 1989-06-20 1993-09-07 Cedars-Sinai Medical Center Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
US5874464A (en) * 1995-01-13 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Conformationally constrained diacylglycerol analogues
AU6888196A (en) * 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
HUP9901621A3 (en) * 1996-05-30 2002-01-28 Aventis Pharmaceuticals Inc Br Protein kinase c inhibitory activity alkyloxyamino substituted fluorenone derivatives, use thereof, intermediates and preparation of the latters, pharmaceutical compositions containing these compounds
EP0887081B1 (en) * 1997-06-27 2003-04-23 Smithkline Beecham Corporation Human serum glucocorticoid regulated kinase, a target for chronic renal disease and diabetic nephropathy
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
CO4940430A1 (en) * 1997-07-07 2000-07-24 Novartis Ag POLYCLIC COMPOUNDS CONTAINING HYDROGENATED STAUROSPORIN WITH CONVENIENT PHARMACOLOGICAL PROPERTIES AND AN INHIBITING EFFECT ON THE GROWTH OF TUMOR CELLS

Also Published As

Publication number Publication date
NO20015054L (en) 2001-12-14
PL352547A1 (en) 2003-08-25
CN1351496A (en) 2002-05-29
DE19917990A1 (en) 2000-11-02
HUP0200819A2 (en) 2002-07-29
EP1171131A1 (en) 2002-01-16
UA79066C2 (en) 2007-05-25
KR20020012172A (en) 2002-02-15
NO20015054D0 (en) 2001-10-17
MXPA01010588A (en) 2004-09-06
SK14972001A3 (en) 2002-06-04
CZ20013778A3 (en) 2002-06-12
ZA200108610B (en) 2002-01-02
CA2369078A1 (en) 2000-10-26
KR100718900B1 (en) 2007-05-17
AU779941B2 (en) 2005-02-17
AU4297200A (en) 2000-11-02
RU2288718C9 (en) 2008-04-27
JP2002542196A (en) 2002-12-10
HUP0200819A3 (en) 2009-08-28
WO2000062781A1 (en) 2000-10-26
PL198427B1 (en) 2008-06-30
RU2288718C2 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
BR0009914A (en) Medication, and, uses of an inhibitor, and a human volume-regulated human h-sgk kinase activator
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
FI951454A (en) 1- (2-oxoacetyl) piperidine-2-carboxylic acid derivatives as sensitizers of multimedia drug resistant cancer cells
BRPI0416602A (en) n-acylsulfonamide apoptosis promoters
BR0308854A (en) Substituted benzazoles and their uses as raf kinase inhibitors
BR0312464A (en) Tyrosine kinase inhibitors
DE50310516D1 (en) Fredericamycin DERIVATIVES
ATE442142T1 (en) FREDERICAMYCIN DERIVATIVES AS DRUGS FOR TUMOR TREATMENT
BR0312023A (en) Compound, glucose kinase activating compound, method for preventing hypoglycemia, use of a compound, and pharmaceutical composition
ATE469136T1 (en) INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
UY28213A1 (en) NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS.
BRPI0414876A (en) pharmaceutical compounds and compositions for the prevention of overdose or abuse and their uses
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
MXPA05013637A (en) Gsk-3 inhibitors and uses thereof.
DE69718734T2 (en) Bicyclic aromatic compounds
BR9702074A (en) Heterocyclic biaryl compounds pharmaceutical and cosmetic compositions containing them and their uses
ATE200661T1 (en) BISAROMATIC COMPOUNDS, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM AND USES
MX9501849A (en) New bicyclic-aromatic compounds, pharmaceutical and cosmetic compositions containing them and their uses.
BRPI0415753A (en) method for treating and preventing respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions containing them
DE69812100T2 (en) MEDICINAL PRODUCT CONTAINING ADENOSINE
ES2110057T3 (en) MEDICINAL COMPOSITION CONTAINING TCF-II.
AR039394A1 (en) USE OF PTX3 LONG PENTRAXINE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF TUMOR DISEASES ASSOCIATED WITH THE ABNORMAL ACTIVATION OF THE FGF-8 GROWTH FACTOR

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII), 10 (IX), 11, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.